Hardy Reed’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.18M Sell
1,281
-5
-0.4% -$5.07K 0.09% 89
2025
Q4
$1.38M Buy
1,286
+82
+7% +$78.4K 0.1% 83
2025
Q3
$919K Buy
1,204
+168
+16% +$125K 0.07% 98
2025
Q2
$808K Sell
1,036
-72
-6% -$55.9K 0.06% 103
2025
Q1
$915K Buy
1,108
+610
+122% +$508K 0.08% 98
2024
Q4
$384K Sell
498
-3
-0.6% -$2.48K 0.03% 154
2024
Q3
$444K Buy
+501
New +$450K 0.04% 147
2024
Q1
Sell
-627
Closed -$365K 124
2023
Q4
$365K Buy
627
+227
+57% +$133K 0.05% 80
2023
Q3
$215K Buy
+400
New +$206K 0.04% 99

Other funds holding LLY

Hardy Reed's LLY Position: Q1 2026 in Review

Hardy Reed reduced its Eli Lilly (LLY) stake by 0.39% in Q1 2026, selling an estimated $5.07K and leaving 1,281 shares worth $1.18M. The position accounts for 0.09% of the portfolio, ranked #89.

Hardy Reed first reported a position in LLY in Q3 2023 and has held it in 9 quarters since. The position peaked at $1.38M in Q4 2025. 4,355 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Hardy Reed held 1,281 shares of Eli Lilly worth $1.18M as of Q1 2026.
  • Hardy Reed sold 5 Eli Lilly shares in Q1 2026, an estimated $5.07K.
  • Eli Lilly made up 0.09% of Hardy Reed's portfolio in Q1 2026, its #89 holding.
  • Hardy Reed first reported a position in Eli Lilly in Q3 2023 and has held it in 9 quarters since.
  • Hardy Reed's Eli Lilly position peaked at $1.38M in Q4 2025.
  • 4,355 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Hardy Reed's 13F filing for Q1 2026, filed 28 Apr 2026.